Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
May 9th 2023Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.
Read More